September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Pharmacological Inhibition of Paxillin Reduces Cell Proliferation in Uveal Melanoma Cell Lines
Author Affiliations & Notes
  • Bradley Gao
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Levon Djenderedjian
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • William Coppess
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Zachary Goldsmith
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Matthew W Wilson
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
    Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
  • Vanessa Marie Morales
    Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States
    Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Footnotes
    Commercial Relationships   Bradley Gao, None; Levon Djenderedjian, None; William Coppess, None; Zachary Goldsmith , None; Matthew Wilson, None; Vanessa Morales, None
  • Footnotes
    Support  Research to Prevent Blindness, SJCRH Endowment
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Bradley Gao, Levon Djenderedjian, William Coppess, Zachary Goldsmith, Matthew W Wilson, Vanessa Marie Morales; Pharmacological Inhibition of Paxillin Reduces Cell Proliferation in Uveal Melanoma Cell Lines. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4118.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Uveal Melanoma (UM) is the most common primary intraocular tumor in adults. Predominantly, it presents in the choroid, but may also be present in the iris and ciliary body. Here, we investigate the contributions of the cytoskeletal adaptor paxillin in UM cell cycle regulation by using the paxillin inhibitor 6-B345TTQ.

Methods : We cultured the primary UM cell lines Mel270 and 92.1 in the presence or absence of 20ng/mL of Hepatocyte Growth Factor (HGF), which is highly abundant in the liver microenvironment and exposed them to increasing concentrations of the paxillin inhibitor 6-B345TTQ. We investigated the percentage of cells expressing the cyclins associated with G1 and S phase, namely Cyclin D1, E and A, and the inhibitors p21 and p27.

Results : Our work shows a significant reduction in the percentage of UM expressing Cyclin E, required to transition from G1 to S, when treated by paxillin inhibitor or by paxillin inhibitor and HGF in primary UM cells [untreated: 4.87%±0.24; paxillin: 3.06%±0.4; paxillin + HGF: 3.7%±0.47; p=0.0006]. We also examined p21, shown to be high in invasive UM, and found Mel270 showed a reduction in p21 levels in HGF + paxillin inhibitor (p=0.08) cultures. UM cell line 92.1 also showed a significant reduction in p21 (p=0.05).

Conclusions : More experiments are underway to delineate the potential role of inhibition of paxillin to control UM cell proliferation. Our results suggest inhibition of paxillin could be used as an adjunct therapy in UM.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×